Literature DB >> 25127689

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.

Tapan K Bera1, Masanori Onda1, Robert J Kreitman1, Ira Pastan2.   

Abstract

Moxetumomab pasudotox (HA22) is a recombinant immunotoxin, now in clinical trials, that combines an anti-CD22-Fv with a 38-kDa fragment of Pseudomonas exotoxin A. To produce a less immunogenic molecule without reducing the half-life in circulation, we constructed LMB11 combining an anti-CD22 Fab with a less immunogenic version of PE38. We found that LMB11 retains full activity toward CD22-expressing cells. In mice, the half-life of LMB11 is 29 min and the antitumor activity of LMB11 is better than that of HA22. Because it can be safely given at much higher doses, LMB11 produced complete tumor remissions in 7/7 mice. Published by Elsevier Ltd.

Entities:  

Keywords:  B-cell malignancies; Less immunogenic PE38; Moxetumomab pasudotox

Mesh：

Substances：

Year:  2014        PMID： 25127689      PMCID： PMC4182334          DOI： 10.1016/j.leukres.2014.06.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  16 in total

1.  Recombinant immunotoxins in the treatment of cancer.

Authors:  Ira Pastan; Richard Beers; Tapan K Bera
Journal:  Methods Mol Biol       Date:  2004

2.  Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.

Authors:  Alan S Wayne; Robert J Kreitman; Harry W Findley; Glen Lew; Cynthia Delbrook; Seth M Steinberg; Maryalice Stetler-Stevenson; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 3.  Immunotoxin treatment of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

4.  HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Authors:  Sookhee Bang; Satoshi Nagata; Masanori Onda; Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 5.  Therapeutic application of monoclonal antibodies in cancer: advances and challenges.

Authors:  Helmout Modjtahedi; Sumaira Ali; Sharadah Essapen
Journal:  Br Med Bull       Date:  2012-10-31       Impact factor: 4.291

6.  Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.

Authors:  T K Bera; I Pastan
Journal:  Bioconjug Chem       Date:  1998 Nov-Dec       Impact factor: 4.774

7.  Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Maryalice Stetler-Stevenson; Inger Margulies; Pierre Noel; David J P Fitzgerald; Wyndham H Wilson; Ira Pastan
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

8.  A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Authors:  John E Weldon; Laiman Xiang; Oleg Chertov; Inger Margulies; Robert J Kreitman; David J FitzGerald; Ira Pastan
Journal:  Blood       Date:  2008-11-06       Impact factor: 25.476

9.  Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.

Authors:  R J Kreitman; Q C Wang; D J FitzGerald; I Pastan
Journal:  Int J Cancer       Date:  1999-03-31       Impact factor: 7.316

10.  A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

Authors:  Johanna K Hansen; John E Weldon; Laiman Xiang; Richard Beers; Masanori Onda; Ira Pastan
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.912
View more
  19 in total

1.  Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.

Authors:  Ronit Mazor; Gilad Kaplan; Dong Park; Youjin Jang; Fred Lee; Robert Kreitman; Ira Pastan
Journal:  Cell Immunol       Date:  2017-01-05       Impact factor: 4.868

Review 2.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 3.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

4.  Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.

Authors:  Xiufen Liu; Fabian Müller; Alan S Wayne; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

5.  Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.

Authors:  Fabian Müller; Tyler Cunningham; Xiu Fen Liu; Alan S Wayne; Ira Pastan
Journal:  Clin Cancer Res       Date:  2016-04-25       Impact factor: 12.531

6.  Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.

Authors:  John E Weldon; Martin Skarzynski; Jamy A Therres; Joshua R Ostovitz; Hong Zhou; Robert J Kreitman; Ira Pastan
Journal:  Bioconjug Chem       Date:  2015-06-03       Impact factor: 6.069

Review 7.  Immunogenicity of therapeutic recombinant immunotoxins.

Authors:  Ronit Mazor; Masanori Onda; Ira Pastan
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 10.983

Review 8.  CCR9 in cancer: oncogenic role and therapeutic targeting.

Authors:  Zhenbo Tu; Ruijing Xiao; Jie Xiong; Kingsley M Tembo; Xinzhou Deng; Meng Xiong; Pan Liu; Meng Wang; Qiuping Zhang
Journal:  J Hematol Oncol       Date:  2016-02-16       Impact factor: 17.388

9.  Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering.

Authors:  Gilad Kaplan; Ronit Mazor; Fred Lee; Youjin Jang; Yasmin Leshem; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2018-04-25       Impact factor: 6.009

10.  Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.

Authors:  Pietro Della Cristina; Monica Castagna; Alessio Lombardi; Erika Barison; Giovanni Tagliabue; Aldo Ceriotti; Ilias Koutris; Luana Di Leandro; Francesco Giansanti; Riccardo Vago; Rodolfo Ippoliti; Sopsamorn U Flavell; David J Flavell; Marco Colombatti; Maria Serena Fabbrini
Journal:  Microb Cell Fact       Date:  2015-02-13       Impact factor: 6.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.